Sanofi Rebounds with $329M Blackstone Infusion for Multiple Myeloma Drug
Summary
In 2020 the FDA approved Sarclisa in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy. Earlier this month, Blackstone led a $200 million financing round for California-based DNAnexus, Inc. to advance the global adoption of its cloud-based biomedical data analysis software. Last year, Blackstone provided Autolus Therapeutics with $250 million in funding to support that companys development of obecabtagene autoleucel (obe-cel), a CD19 CAR T cell investigational therapy product candidate. John Reed, Sanofis global head of research and development, noted that the collaboration with Blackstone is expected to accelerate the companys ability to provide the subcutaneous formulation of Sarclisa to patients in a manner they believe will be more innovative and more convenient. "We are committed to building an industry-leading, sustainable pipeline with a steady stream of new therapies that have the potential to transform the practice of medicine," Reed said in a brief statement.